Purpose: A large part of the national opioid epidemic has been tied to prescription opioids, leading to a push to reduce or eliminate their use when feasible. The objective of this study was to evaluate outcomes of implementing an Enhanced Recovery After Surgery (ERAS) protocol for patients undergoing ureteroscopic stone treatment with stent placement geared toward minimizing opioid use. Materials and Methods: We performed a pre-post study concerning a process improvement project of consecutive patients undergoing ureteroscopic stone treatment with stent placement utilizing a novel ERAS protocol. A lead-in period with patients managed conventionally with opioids was performed before implementation of the ERAS protocol. Data regarding opioid utilization, postoperative outcomes, and patient-reported outcomes, including Patient-Reported Outcomes Measurement Information System (PROMIS), were compared between groups. Results: There were 28 pre-ERAS patients and 52 ERAS-managed patients. Patients discharged with an opioid prescription decreased from 93% to 0% (p < 0.05). Mean total morphine milligram equivalent decreased from 60.1 ± 41 to 7.7 ± 26 (p < 0.05). There was no significant difference noted for postoperative calls for pain in the pre-ERAS vs ERAS groups (25% vs 19%, p = 0.9) or in unscheduled provider encounters (0% vs 4%, p = 0.46). There were no clinically significant differences between groups on patient-reported measures. Conclusions: Implementation of an ERAS protocol for ureteroscopic stone treatment resulted in a significant reduction in perioperative opioids, a total reduction in discharge opioid prescriptions, and ∼90% reduction in total 30-day postoperative opioid prescribing with no adverse effects on recovery or increase in postoperative clinical encounters.
Purpose: A large part of the national opioid epidemic has been tied to prescription opioids, leading to a push to reduce or eliminate their use when feasible. The objective of this study was to evaluate outcomes of implementing an Enhanced Recovery After Surgery (ERAS) protocol for patients undergoing ureteroscopic stone treatment with stent placement geared toward minimizing opioid use. Materials and Methods: We performed a pre-post study concerning a process improvement project of consecutive patients undergoing ureteroscopic stone treatment with stent placement utilizing a novel ERAS protocol. A lead-in period with patients managed conventionally with opioids was performed before implementation of the ERAS protocol. Data regarding opioid utilization, postoperative outcomes, and patient-reported outcomes, including Patient-Reported Outcomes Measurement Information System (PROMIS), were compared between groups. Results: There were 28 pre-ERAS patients and 52 ERAS-managed patients. Patients discharged with an opioid prescription decreased from 93% to 0% (p < 0.05). Mean total morphine milligram equivalent decreased from 60.1 ± 41 to 7.7 ± 26 (p < 0.05). There was no significant difference noted for postoperative calls for pain in the pre-ERAS vs ERAS groups (25% vs 19%, p = 0.9) or in unscheduled provider encounters (0% vs 4%, p = 0.46). There were no clinically significant differences between groups on patient-reported measures. Conclusions: Implementation of an ERAS protocol for ureteroscopic stone treatment resulted in a significant reduction in perioperative opioids, a total reduction in discharge opioid prescriptions, and ∼90% reduction in total 30-day postoperative opioid prescribing with no adverse effects on recovery or increase in postoperative clinical encounters.
Authors: Ehsan Jazini; Alexandra E Thomson; Andre D Sabet; Omar Sohail; Leah Y Carreon; Lindsay Orosz; Fenil R Bhatt; Rita Roy; Colin M Haines; Thomas C Schuler; Christopher R Good Journal: Spine Deform Date: 2021-11-06
Authors: Scott R Hawken; Spencer C Hiller; Stephanie Daignault-Newton; Khurshid R Ghani; John M Hollingsworth; Bronson Conrado; Conrad Maitland; David L Wenzler; John K Ludlow; Sapan N Ambani; Chad M Brummett; Casey A Dauw Journal: Urology Date: 2021-09-01 Impact factor: 2.649
Authors: Alex M Kasman; Bogdana Schmidt; Kyle Spradling; Charlene Chow; Rebecca Hunt; Mechele Wu; Alexa Sockol; Joseph Liao; John T Leppert; Jay Shah; Simon L Conti Journal: Curr Urol Date: 2021-05-26
Authors: Sarah Huepenbecker; Robert Tyler Hillman; Maria D Iniesta; Tsun Chen; Katherine Cain; Gabriel Mena; Javier Lasala; Xin Shelley Wang; Loretta Williams; Jolyn S Taylor; Karen H Lu; Pedro T Ramirez; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2021-06-16 Impact factor: 4.661